Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.

Détails

ID Serval
serval:BIB_D14BA5B24F02
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
Périodique
International journal of cancer
Auteur(s)
Sarrabayrouse G., Pich C., Teiti I., Tilkin-Mariame A.F.
ISSN
1097-0215 (Electronic)
ISSN-L
0020-7136
Statut éditorial
Publié
Date de publication
15/02/2017
Peer-reviewed
Oui
Volume
140
Numéro
4
Pages
747-755
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Melanoma is a highly lethal cutaneous tumor, killing affected patients through development of multiple poorly immunogenic metastases. Suboptimal activation of immune system by melanoma cells is often due to molecular modifications occurring during tumor progression that prevent efficient recognition of melanoma cells by immune effectors. Statins are HMG-CoA reductase inhibitors, which block the mevalonate synthesis pathway, used by millions of people as hypocholesterolemic agents in cardiovascular and cerebrovascular diseases. They are also known to inhibit Rho GTPase activation and Rho dependent signaling pathways. Rho GTPases are regarded as molecular switches that regulate a wide spectrum of cellular functions and their dysfunction has been characterized in various oncogenic process notably in melanoma progression. Moreover, these molecules can modulate the immune response. Since 10 years we have demonstrated that Statins and other Rho GTPases inhibitors are critical regulators of molecules involved in adaptive and innate anti-melanoma immune response. In this review we summarize our major observations demonstrating that these pharmacological agents stimulate melanoma immunogenicity and suggest a potential use of these molecules to promote anti-melanoma immune response.

Mots-clé
Adaptive Immunity/drug effects, Adjuvants, Immunologic/pharmacology, Adjuvants, Immunologic/therapeutic use, Animals, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Disease Progression, Enzyme Activation/drug effects, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Immunity, Innate/drug effects, Melanoma/drug therapy, Melanoma/immunology, Melanoma, Experimental/drug therapy, Melanoma, Experimental/immunology, Mevalonic Acid/metabolism, Mice, Molecular Targeted Therapy, Neoplasm Proteins/antagonists & inhibitors, Neoplasm Proteins/physiology, Protein Prenylation/drug effects, Signal Transduction/drug effects, rho GTP-Binding Proteins/antagonists & inhibitors, rho GTP-Binding Proteins/physiology, Rho GTPases, immunotherapy, melanoma, protein prenylation, statins
Pubmed
Web of science
Création de la notice
12/01/2017 16:26
Dernière modification de la notice
03/03/2018 21:37
Données d'usage